Dasatinib: A Guide to Its Use in Chronic Myeloid Leukemia in the EU
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Oral dasatinib (Sprycel®) is effective in the treatment of patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML) or imatinib-resistant or imatinib-intolerant chronic-phase, accelerated-phase, or blast-phase CML. In particular, dasatinib is associated with better and faster responses than imatinib in patients with newly diagnosed chronic-phase CML. The response to dasatinib appears to be maintained in the longer-term. Dasatinib has an acceptable tolerability profile; it is associated with myelosuppression, with fluid retention being the most common nonhematologic adverse event. Thus, dasatinib is a highly effective, once-daily therapy for the first-line treatment of patients with chronic-phase CML and for the second-line treatment of imatinib-resistant or imatinib-intolerant CML.
- Baccarani M, Dreyling M. Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl. 4):105–7.
- National Comprehensive Cancer Network clinical practice guidelines in oncology (NCCN guidelines): chronic myelogenous leukemia version 2.2013. Fort Washington (PA): National Comprehensive Cancer Network, 2012.
- McCormack PL, Keam SJ. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs. 2011;71(13):1771–95. CrossRef
- Condorelli F, Genazzani AA. Dasatinib: is it all in the dose? BioDrugs. 2010;24(3):157–63. CrossRef
- Sprycel (dasatinib) film-coated tablets: summary of product characteristics. London: European Medicines Agency; 2012.
- Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260–70. CrossRef
- Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119(5):1123–9. CrossRef
- Hochhaus A, Boque C, Bradley Garelik M, et al. Molecular response kinetics and BCR-ABL reductions in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib vs imatinib: DASISION 3-year follow-up [poster no. 1537]. 17th Congress of the European Hematology Association, Amsterdam; 14–17 Jun 2012.
- Mayer J, Warzocha K, Huguet F, et al. Efficacy and safety of dasatinib vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): European subpopulation analysis of the phase 3 DASISION trial [abstract no. 0190]. Haematologica. 2012;97(Suppl. 1):75.
- Radich JP, Kopecky KJ, Appelbaum FR, et al. A randomized trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic phase chromic myeloid leukemia. Blood. 2012;120(19):3898–905. CrossRef
- Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010;95(2):232–40. CrossRef
- Rea D, Vellenga E, Junghanss C, et al. Six-year follow-up of patients with imatinib-resistant or imatinib-intolerant chronic-phase chronic myeloid leukemia (CP-CML) receiving dasatinib [poster no. 1430]. 17th Congress of the European Hematology Association, Amsterdam; 14–17 Jun 2012.
- Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009;113(25):6322–9. CrossRef
- Saglio G, Hochhaus A, Goh YT, et al. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer. 2010;116(16):3852–61. CrossRef
- Dasatinib: A Guide to Its Use in Chronic Myeloid Leukemia in the EU
Volume 27, Issue 3 , pp 275-279
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing AG
- Additional Links
- Industry Sectors